Abstract: A kit for mixing comprises a housing accommodating an ampoule containing a solid and a container containing a solvent which is either pre-pressurized or which may be pressurized when it is desired to mix to the liquid and solid components. A needle unit comprises a first needle, the opposite ends of which pierce rubber membranes closing the ampoule and the container, to establish a transport channel through which pressurized solvent flows from the container to the ampoule. The ampoule is vented through a second needle inserted through the membrane of the ampoule and provided with a micro-filter. In one embodiment, the needle unit is displaceable to cause the ends of the needles to pierce the respective membranes, and locked in place by a spring biased locking mechanism. A branch passage from the needle is connected to a cylinder containing a piston coupled to the locking mechanism. When the ampoule is full, pressure in the branch passage will rise, actuating the piston and releasing the locking mechanism.

Abstract: The present invention relates to a method of constructing a variant of a parent Termamyl-like .alpha.-amylase, which variant has .alpha.-amylase activity and at least one altered property as compared to the parent .alpha.-amylase, comprisesi) analyzing the structure of the parent Termamyl-like .alpha.-amylase to identify at least one amino acid residue or at least one structural part of the Termamyl-like .alpha.-amylase structure, which amino acid residue or structural part is believed to be of relevance for altering the property of the parent Termamyl-like .alpha.-amylase (as evaluated on the basis of structural or functional considerations),ii) constructing a Termamyl-like .alpha.-amylase variant, which as compared to the parent Termamyl-like .alpha.-amylase, has been modified in the amino acid residue or structural part identified in i) so as to alter the property, and, optionally,iii) testing the resulting Termamyl-like .alpha.-amylase variant with respect to the property in question.

Abstract: The present invention relates to a compound of general formula I ##STR1## for treating medical disorders related to binding to human somatostatin receptor subtypes.

Abstract: A DNA sequence encoding a lipase having the amino acid sequence shown in SEQ ID NO:2. The lipase has a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule and, located in a critical position of a lipid contact zone of the lipase structure, an amino acid residue different from an aromatic amino acid residue, which amino acid residue interacts with a lipid substrate at or during hydrolysis, in which lipase variant of the amino acid residue has been replaced by an aromatic amino acid residue so as to confer to the variant an increased specific activity as compared to that of the parent lipase.

Abstract: The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Abstract: Cellulose-containing fabric is desized by treating with an enzyme hybrid having a catalytically active amino acid sequence of an enzyme such as a lipase or an amylase linked to an amino acid sequence containing a cellulose-binding domain. The enzyme amino acid sequence may be of an .alpha.-amylase obtainable from a species of Bacillus such as Bacillus licheniformis, or of a lipase obtainable from a species of Humicola, Candida, Pseudomonas or Bacillus. The cellulose-binding domain may be from a cellulase, a xylanase, a mannanase, an arabinofuranosidase, an acetylesterase or a chitinase. The enzyme hybrid is obtained from a transformed host cell containing an expression cassette having a DNA sequence encoding the enzyme hybrid. A desizing composition is formed containing the enzyme hybrid and a wetting agent.

Abstract: This invention relates to Alkalophilic Bacillus sp. AC13 microorganisms and cultures, and mutants and variants thereof, and to enzymes obtainable from the microorganism.

Abstract: The present invention relates to methods for measuring the strength of a healing bone fracture by rotating the bones about their axis at each side of the fracture relative to each other and measure the needed rotational moment as a function of the rotational angle obtained. The present invention also relates to apparatus comprising a first (5) and a second (8) ring shaped member, studs (15) connecting these members (5, 8) with an axial distance from each other, and fixing pins (6, 14) rigidly connecting the respective ring shaped members and the bone (1) at respective sides of the fracture. One ring member (8) comprises a first (10) and a second (9) element joined so that they can be rotated but not axially displaced relative to each other, the first element (10) carrying the studs (15) and the second element (9) carrying the fixing pins (14).

Abstract: The present invention relates to a process for removal or bleaching of soiling or stains present on cellulosic fabric, wherein the fabric is contacted in aqueous medium with a modified enzyme (enzyme hybrid) which comprises a catalytically active amino acid sequence of a non-cellulolytic enzyme linked to an amino acid sequence comprising a cellulose-binding domain. The invention further relates to a detergent composition comprising an enzyme hybrid of the type in question and a surfactant, and to a process for washing soiled or stained cellulosic fabric, wherein the fabric is washed in an aqueous medium to which is added such a detergent composition.

Abstract: The present invention relates to therapeutically active azabicyclic compounds of formula I ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3, Ar, m and n are defined in the description, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

Abstract: There are disclosed novel synthetic peptides of formula (I) ##STR1## where A, B, D, E, F, G, J, m, n, and p are defined in the specification. Compounds of formula (I) promote the release of growth hormone in humans and animals. Growth promoting compositions containing such compounds of formula (I) as the active ingredient, methods of stimulating the release of growth hormone, and the use of such compounds of formula (I) are also disclosed.

Abstract: The present invention relates to fungi, which do not produce proteases. The fungi of the invention are useful as hosts for the production of proteins susceptible of proteolytic degradation by the proteases usually produced, and the invention consequently encompasses processes for the production of proteins of interest in high yields by using the fungi of the invention. The invention also comprises methods for producing such fungi and DNA constructs to be used in these methods.

Abstract: The present invention relates to a method of treating migraine, non-insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation and/or vasomotor disturbances. This method utilizes a hexapeptide of formula (I)A.sup.1 -A.sup.2 -A.sup.3 -A.sup.4 -A.sup.5 -A.sup.6 -Y (I)wherein A.sup.1, A.sup.2, A.sup.3, A.sup.4, A.sup.5, A.sup.6 and Y are as defined in the specification.

Abstract: The present invention relates to a drug delivery system, comprising a reservoir from which set doses are apportioned, a dose setting mechanism by which the relative position of two elements is changed by a distance proportional to a set dose, and a push button by activation of which an element is moved a distance corresponding to the distance proportional to the set dose, further comprises a working cylinder having an open end into which a plunger fits, and a closed end at which an inlet and an outlet port connect the space beneath the plunger with an inlet communicating with the reservoir and an outlet communicating with a drug delivery member, respectively. Valves means at the inlet and outlet control the passages from the reservoir to the working cylinder and from the working cylinder to the drug delivery member, respectively. The cylinder with the plunger, and the injection member are independently exchangeable, disposable parts.

Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the .epsilon.-amino group of Lys.sup.B29 ; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the .epsilon.-amino group of Lys.sup.B29 has a lipophilic substituent; and any Zn.sup.2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and Phe.sup.B1 is present, then the insulin derivative is always present as a Zn.sup.2+ complex.

Abstract: The present invention relates to polypeptides having laccase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides.

Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or-prophylaxis of obesity.

Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxcylic acids of the general formula wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides.

Abstract: The present invention relates to variants of cyclomaltodextrin glucanotransferase. More specifically the invention relates to a method of modifying the substrate binding and/or product selectivity of a precursor CGTase enzyme, and CGTase variants derived from a precursor CGTase enzyme by substitution, insertion and/or deletion of one or more amino acid residue(s), which amino acid residue(s) holds a position close to the substrate. Moreover, the invention relates to DNA constructs encoding the CGTase variants, expression vectors, host cells and methods of producing the CGTase variants of the invention.

Abstract: The present invention relates to an improved displacement device (1) for controlled dispensing of a dose of a liquid contained in a cartridge (40), the displacement device (1) comprises a housing (5) incorporating: a mechanism (6) for accommodating the cartridge (40), a manually activatable displaceable elongated dose dispensing device (20), the elongated dose dispensing device (20) having a first end part (22) extending to the exterior of the housing (5), an elongated piston rod (30) connected with a displaceable piston (32), the piston (32) being adapted to press out the liquid contained in the cartridge (40), and the piston rod (30) having a plurality of transversely extending teeth (25) arranged along its length, a toothed displacing mechanism (14), and a user-operated dose setting mechanism (8,10,12), the user-operated dose setting mechanism (8,10,12) and the toothed displacing mechanism (14) are operatively connected to cause movement of the toothed displacing mechanism (14) in response to the operation